Chronic myeloid leukemia (CML): prognostic factors and survival analysis

Abstract

The prognostic value of different factors upon diagnosis of CML was analysed in 45 Philadelphia (Ph1)-positive patients. The median survival was 48 months. Univariate analysis showed 5 poor prognostic factors (male sex, under 45 years-old, bone marrow blasts greater than or equal to 10 percent, blood basophils greater than or equal to 6 percent and blood eosinophils greater than or equal to 6 percent) which provided for the development of a clinical staging system: Stage I with none or one factor and a two-year survival rate of 100 percent; Stage II with two or three factors and two-year survival of 72.2 percent; and Stage III with four or five factors and two-year survival of 0 percent (p = 0.00016). Multivariate survival analysis showed that combination of blood basophilia and bone marrow blasts had the strongest predictive relationship to survival time. We conclude that a combination of pretreatment factors identifies different risk subcategories in CML patients and is helpful in assessing the overall prognosis and the treatment approach.

Identification of Basogranulin (BB1) as a Novel Immunohistochemical Marker of Basophils in Normal Bone Marrow and Patients With Myeloproliferative Disorders

“…[20][21][22][23] In CML, basophilia invariably is found in all patients. 21,23,24 Moreover, the numbers (percentage) of basophils in BM and peripheral blood smears in CML correlate with (a poor) prognosis. [24][25][26][27][28][29] In fact, a number of clinical studies have shown that basophilia is an independent adverse prognostic variable in patients with CML.…”

“…21,23,24 Moreover, the numbers (percentage) of basophils in BM and peripheral blood smears in CML correlate with (a poor) prognosis. [24][25][26][27][28][29] In fact, a number of clinical studies have shown that basophilia is an independent adverse prognostic variable in patients with CML. 24,27,29 In addition, basophils typically increase in number in the peripheral blood and in the BM during acceleration of CML.…”

Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7

“…[19][20][21] In addition, an increased percentage of basophils in the bone marrow and in the peripheral blood in CML is associated with a poor prognosis. [23][24][25][26][27][28][29] Thus basophilia is an independent adverse prognostic variable in CML. [27][28][29] Moreover, basophils typically increase in number in the bone marrow as well as in the blood during disease acceleration.…”

“…[23][24][25][26][27][28][29] Thus basophilia is an independent adverse prognostic variable in CML. [27][28][29] Moreover, basophils typically increase in number in the bone marrow as well as in the blood during disease acceleration. [23][24][25][26][27] Basophils originate from the malignant clone in patients with CML.…”

“…[27][28][29] Moreover, basophils typically increase in number in the bone marrow as well as in the blood during disease acceleration. [23][24][25][26][27] Basophils originate from the malignant clone in patients with CML. 30 31 However, whereas basophilia can readily be quantified in the peripheral blood and on bone marrow smears, no generally accepted and easily applicable staining protocol for the identification and quantification of basophils in bone marrow biopsy sections has become available so far.…”